GDTC Earning Date, Earning Analysis and Earning Prediction
Earning Analysis
Welcome to our in-depth analysis of CytoMed Therapeutics Ltd(GDTC) earnings, offering investors a detailed look into the company’s financial performance, revenue trends, earnings per share (EPS), and market reactions. This page provides a comprehensive overview of CytoMed Therapeutics Ltd earnings history, forecasts, and key financial metrics, empowering you with the data needed to make informed investment decisions. Whether you're tracking quarterly results, analyzing earnings surprises, or exploring future projections, our detailed breakdown covers it all.
Earnings Forecast
Revenue
EPS
Currency:
No data
Actual
Estimate
Surprise Analysis
Name
EPS
Revenue
Price Reaction
Fiscal Quarter
Earning Date
Time
Estimate
Actual
Surprise%
Estimate
Actual
Surprise%
1D
5D
No data
GDTC Earnings Analysis
Our earnings analysis provides a granular look at the company’s performance across recent fiscal quarters, highlighting key metrics such as revenue, EPS, and operating margins. By examining actual results against analyst estimates, we uncover trends and surprises that drive stock price movements, offering valuable insights for both short-term traders and long-term investors.
In the most recent quarter, CytoMed Therapeutics Ltd reported performance for , announced on . The company achieved an EPS of , compared to analyst estimates of by % . Revenue for the quarter reached undefined compared to expectations of undefined by % .
The stock price reacted with a % one-day change and a % five-day change following the earnings release. These movements reflect market reaction in CytoMed Therapeutics Ltd growth trajectory and strategic initiatives.
GDTC Earnings Forecast
Looking ahead, CytoMed Therapeutics Ltd(GDTC) remains a focal point for investors seeking growth opportunities. Analyst forecasts for project quarter revenue of undefined and an EPS of undefined.
However, recent estimate revisions provide additional context. Over the past three months, revenue estimates for FY2025 have been No Change by 0%, while EPS estimates have been No Change by 0%. For the upcoming Q3 2025, revenue estimates have been adjusted No Change by 0% . These revisions correlate with a -17.10% change in stock price over the same period, suggesting potential buying opportunities for investors who believe in CytoMed Therapeutics Ltd long-term fundamentals.
The relationship between earnings forecast revisions and stock price movements is critical for investors. Positive revisions in revenue or EPS often signal strengthening fundamentals, making temporary price dips attractive entry points. Conversely, downward revisions may reflect short-term challenges.
Estimate Revision
The chart shows the correlation between GDTC's stock price and earnings forecast revisions. Positive revisions in Revenue or EPS often strengthen the stock's fundamentals, making price dips potential buying opportunities.
Revenue Estimates for FY2025
No Change
0.00%
In Past 3 Month
EPS Estimates for FY2025
No Change
0.00%
In Past 3 Month
Revenue Estimates for Q3 2025
No Change
0.00%
In Past 3 Month
Stock Price
Go Down
-17.10%
In Past 3 Month
1Y
3Y
5Y
Currency: USD
Currency: USD
1Y
3Y
5Y
--
Revenue Estimate-Annual FY 2025:520.00K
--
EPS Estimate-Annual FY 2025:-0.17
—
Stock Price1.60
GDTC Revenue and EPS Performance: A Historical Perspective
CytoMed Therapeutics Ltd revenue and earnings per share (EPS) performance over recent quarters provides a clear picture of its financial health. Below is a detailed breakdown of the company’s earnings history, showcasing actual results, analyst estimates, and surprise percentages for key fiscal quarters:
(,):
EPS: (Actual) vs. (Estimate) (%)
Revenue: undefined (Actual) vs. undefined (Estimate) (%)
Price Reaction:%(1-Day), %(5-Day)
(,):
EPS: (Actual) vs. (Estimate) (%)
Revenue: undefined (Actual) vs. undefined (Estimate) (%)
Price Reaction:%(1-Day), %(5-Day)
(,):
EPS: (Actual) vs. (Estimate) (%)
Revenue: undefined (Actual) vs. undefined (Estimate) (%)
Price Reaction:%(1-Day), %(5-Day)
Earnings Reaction
The chart below shows how GDTC performed 10 days before and after its earnings report, based on data from the past quarters. Typically, GDTC sees a +0.00% change in stock price 10 days leading up to the earnings, and a +0.00% change 10 days following the report. On the earnings day itself, the stock moves by +0.00%. This data can give you a slight idea of what to expect for the next quarter's release.
For example, in , the stock changed % on the day following the earnings release and then changed by % over the next 10 days. These patterns provide investors with valuable insights into potential price movements and help inform trading strategies around earnings events.
No data
Transcript Summary
People Also Watch
Frequently Asked Questions
What were the key highlights of GDTC's latest earnings report for undefined?
GDTC reported its earnings on , showcasing a revenue of undefined against an estimate of undefined, resulting in a NaN% surprise. The EPS was NaN, surpassing the expected NaN by NaN% . The stock experienced a NaN% price change on the earnings day and a NaN% change over the next five days, reflecting market reactions to the results.
How did GDTC's stock price react after the undefined earnings release?
Following GDTC's earnings announcement on , the stock price moved by % on the day of the release. Over the subsequent five days, it saw a % change. Historically, GDTC's stock price tends to shift by an average of +0.00% in the 10 days leading up to earnings and +0.00% in the 10 days following, providing insight into potential market.
What are the revenue and EPS estimates for GDTC for undefined?
For , analysts estimate GDTC’s annual revenue to reach undefined, while the EPS is projected at undefined. These estimates reflect recent revisions, with revenue estimates revised Revenue No Change by 0% and EPS estimates No Change by 0% over the past three months, indicating analyst expectation in the company’s performance.
How does GDTC's stock price correlate with earnings forecast revisions?
The correlation between GDTC's stock price and earnings forecast revisions shows that positive revisions in revenue or EPS often strengthen the stock’s fundamentals. Over the past three months, revenue estimates for FY2025 were No Change by 0%, while EPS estimates moved No Change by 0% . This trend suggests that price dips could present buying opportunities for investors.
What should investors expect from GDTC's next earnings report?
Based on historical trends, GDTC's stock price typically moves by +0.00% in the 10 days before its earnings and +0.00% in the 10 days after. For the upcoming earnings, analysts expect an EPS of undefined and revenue of undefined.
What is the sentiment in CytoMed Therapeutics Ltd (GDTC) Q2 2025 Earnings Call Summary?
The earnings call reveals several concerning factors: significant net loss, decreasing cash reserves, increased research and operational costs, and financial risks from currency exchange and warrant liabilities. Despite a 100% revenue increase, the financial outlook is weak, with heavy reliance on fundraising. The Q&A section lacks clarity, which may further unsettle investors. Overall, negative sentiment prevails due to financial instability and operational challenges.
